A computational study of Di-substituted 1,2,3-triazole derivatives as potential drug candidates against Mycobacterium tuberculosis : 3D-QSAR, molecular docking, molecular dynamics, and ADMETox
Multidrug-resistant TB (MDR TB) strains have become a severe issue, motivating researchers to find new TB drugs effective against these MDR strains. In this work, 3D-QSAR (three-dimensional quantitative structure-activity relationship), molecular docking, ADMET, and molecular dynamics studies were p...
Gespeichert in:
Veröffentlicht in: | New journal of chemistry 2023-06, Vol.47 (25), p.11832-11841 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Multidrug-resistant TB (MDR TB) strains have become a severe issue, motivating researchers to find new TB drugs effective against these MDR strains. In this work, 3D-QSAR (three-dimensional quantitative structure-activity relationship), molecular docking, ADMET, and molecular dynamics studies were performed to investigate the inhibitory activity of 1,2,3-triazole derivatives against
Mycobacterium tuberculosis
by acting as H37Rv active site inhibitors. The 3D-QSAR study was conducted based on molecular field comparative analysis (CoMFA) and molecular similarity index benchmarking (CoMSIA), which revealed CoMFA model values (
Q
2
= 0.62;
R
2
= 0.95) and CoMSIA model values (
Q
2
= 0.57;
R
2
= 0.84) for the best-observed models. These values presented excellent predictability, which was also evaluated by using the criteria established by A. Golbraikh and A. Tropsha. A molecular docking interaction between the Gln164 and Lys160 residues was observed at the mycobacterial active site H37Rv, as verified by the interaction type, total score, and MD molecular dynamics. Furthermore, the ADMET properties and drug similarity of these new inhibitors were analyzed. Our results can help researchers synthesize new therapeutic candidates against multidrug-resistant tuberculosis. |
---|---|
ISSN: | 1144-0546 1369-9261 |
DOI: | 10.1039/D3NJ01649H |